# Role of Co-trimoxazole in Severe COVID-19 Patients

> **NCT04470531** · PHASE2 · UNKNOWN · sponsor: **Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh** · enrollment: 94 (estimated)

## Conditions studied

- Covid19
- Severe COVID-19 Patients

## Interventions

- **DRUG:** oral co-trimoxazole

## Key facts

- **NCT ID:** NCT04470531
- **Lead sponsor:** Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-07-12
- **Primary completion:** 2020-10-12
- **Final completion:** 2021-01-30
- **Target enrollment:** 94 (ESTIMATED)
- **Last updated:** 2020-07-16

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04470531

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04470531, "Role of Co-trimoxazole in Severe COVID-19 Patients". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT04470531. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*